CEO Stephen MacMillan was paid $15,819,261 in fiscal year 2024, ↑ up 1.7% from fiscal year 2023, the 50th percentile of its disclosed peer group (SEC filing 0001140361-25-001287 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$15,819,261 ↑ Stephen MacMillan total, FY2024 | 50th CEO pay percentile vs peers | 137:1 CEO-to-median pay ratio | 83.56% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Stephen MacMillan | $1,212,628 | $0 | $9,141,468 | $2,937,477 | $1,990,413 | $0 | $537,275 | $15,819,261 |
| Chairman, President and Chief Executive Officer | ||||||||
| Karleen Oberton | 694,231 | 0 | 1,944,766 | 624,995 | 600,000 | 0 | 226,446 | 4,090,438 |
| Chief Financial Officer | ||||||||
| Essex Mitchell | 592,692 | 0 | 1,944,766 | 624,995 | 725,000 | 0 | 196,272 | 4,083,725 |
| Chief Operating Officer | ||||||||
| Jan Verstreken | 693,399 | 0 | 1,555,966 | 499,996 | 611,323 | 0 | 225,211 | 3,585,895 |
| Group President, International | ||||||||
| John Griffin | 644,231 | 0 | 1,555,966 | 499,996 | 550,000 | 0 | 223,858 | 3,474,051 |
| General Counsel | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Stephen MacMillan | $15,819,261 | $15,555,032 | $14,335,632 | ↑ +264,229 |
| Karleen Oberton | 4,090,438 | 3,934,620 | 3,597,619 | ↑ +155,818 |
| Essex Mitchell | 4,083,725 | 2,172,586 | — | ↑ +1,911,139 |
| Jan Verstreken | 3,585,895 | 3,523,984 | 2,753,419 | ↑ +61,911 |
| John Griffin | 3,474,051 | 3,341,111 | 3,242,089 | ↑ +132,940 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read HOLOGIC INC's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper HOLX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the HOLOGIC INC Peer Teardown Report
$15,819,261 Stephen MacMillan total, FY2024
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 1, 2026 · Source: 0001140361-25-001287 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for HOLX
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order HOLX
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses HOLX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named HOLX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the HOLOGIC INC Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Amy M. Wendell | Lead Independent Director | $357,452 |
| Charles J. Dockendorff | Independent Director | $354,952 |
| Christiana Stamoulis | Independent Director | $329,952 |
| Ludwig N. Hantson | Independent Director | $329,952 |
| Namal Nawana | Independent Director | $45,000 |
| Nanaz Mohtashami | Independent Director | $329,952 |
| Sally W. Crawford | Independent Director | $357,452 |
| Scott T. Garrett | Independent Director | $349,952 |
| Stacey D. Stewart | Independent Director | $329,952 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Stephen P. MacMillan | Director | 2025-09-22 | D | 138,358 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2025-09-22 | D | 77,418 | 67 | 5,190,103 | Deferred share award | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2025-09-22 | D | 22,240 | 66 | 1,470,731 | Deferred share award | Form 4 ↗ |
| Christiana Stamoulis | Director | 2025-10-20 | D | 7,402 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2025-10-20 | D | 7,402 | 73 | 540,864 | Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2025-10-20 | A | 7,402 | 36 | 266,768 | Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2025-11-04 | A | 2,656 | — | — | Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2025-11-04 | A | 17,095 | — | — | Deferred share award | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2025-11-04 | A | 15,196 | — | — | Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2025-11-04 | A | 83,589 | — | — | Deferred share award | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2025-11-04 | A | 9,116 | — | — | Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2025-11-04 | A | 2,278 | — | — | Deferred share award | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2025-11-07 | D | 288 | 74 | 21,341 | Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2025-11-07 | D | 3,927 | 74 | 290,991 | Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2025-11-07 | D | 9,427 | 74 | 698,541 | Deferred share award | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2025-11-07 | D | 158 | 74 | 11,708 | Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2025-11-07 | D | 138 | 74 | 10,226 | Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2025-11-07 | D | 1,078 | 74 | 79,880 | Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2025-11-07 | D | 50,405 | 74 | 3,735,011 | Deferred share award | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2025-11-07 | D | 1,420 | 74 | 105,222 | Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2025-11-10 | A | 17,496 | — | — | Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2025-11-10 | A | 13,458 | — | — | Deferred share award | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2025-11-10 | A | 43,741 | — | — | Deferred share award | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2025-11-10 | A | 30,282 | — | — | Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2025-11-10 | A | 169,582 | — | — | Deferred share award | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2025-11-10 | A | 5,047 | — | — | Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2025-11-10 | A | 12,113 | — | — | Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2025-11-10 | A | 16,823 | — | — | Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2025-11-10 | A | 47,106 | — | — | Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2025-11-11 | D | 289 | 75 | 21,559 | Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2025-11-11 | D | 406 | 75 | 30,288 | Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2025-11-11 | D | 1,701 | 75 | 126,895 | Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2025-11-11 | D | 1,449 | 75 | 108,095 | Deferred share award | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2025-11-11 | D | 702 | 75 | 52,369 | Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2025-11-11 | D | 178 | 75 | 13,279 | Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2025-11-11 | D | 181 | 75 | 13,503 | Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2025-11-11 | D | 6,679 | 75 | 498,253 | Deferred share award | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2025-11-14 | D | 1,342 | 74 | 99,509 | Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2025-11-14 | D | 178 | 74 | 13,199 | Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2025-11-14 | D | 337 | 74 | 24,989 | Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2025-11-14 | D | 187 | 74 | 13,866 | Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2025-11-14 | D | 1,333 | 74 | 98,842 | Deferred share award | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2025-11-14 | D | 561 | 74 | 41,598 | Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2025-11-14 | D | 6,874 | 74 | 509,707 | Deferred share award | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2025-11-14 | D | 196 | 74 | 14,533 | Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2025-12-12 | D | 90 | 75 | 6,750 | Common | Form 4 ↗ |
| De Walt Diana | SVP, Human Resources | 2026-01-30 | D | 4,416 | 75 | 330,891 | Common | Form 4 ↗ |
| De Walt Diana | SVP, Human Resources | 2026-01-30 | D | 4,416 | 75 | 330,891 | Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-02-10 | D | 113 | 75 | 8,492 | Deferred share award | Form 4 ↗ |
| Nanaz Mohtashami | Director | 2026-02-26 | A | 3,190 | — | — | Common | Form 4 ↗ |
| Stacey D. Stewart | Director | 2026-02-26 | A | 3,190 | — | — | Deferred share award | Form 4 ↗ |
| Martin Madaus | Director | 2026-02-26 | A | 3,190 | — | — | Common | Form 4 ↗ |
| Wayde D. McMillan | Director | 2026-02-26 | A | 3,190 | — | — | Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-02-26 | A | 3,190 | — | — | Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-02-26 | A | 3,190 | — | — | Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-02-26 | A | 3,190 | — | — | Deferred share award | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-02-26 | A | 3,190 | — | — | Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-02-27 | D | 185 | 75 | 13,942 | Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-04-07 | D | 16,146 | — | — | Deferred share award | Form 4 ↗ |
| Wayde D. McMillan | Director | 2026-04-07 | D | 4,932 | — | — | Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 29,002 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 13,971 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | D | 3,452 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2026-04-07 | D | 3,382 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Madaus | Director | 2026-04-07 | D | 5,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stacey D. Stewart | Director | 2026-04-07 | D | 5,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 6,816 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | A | 3,452 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2026-04-07 | D | 5,665 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2026-04-07 | D | 3,505 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2026-04-07 | D | 7,132 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-04-07 | D | 5,055 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Madaus | Director | 2026-04-07 | D | 1,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nanaz Mohtashami | Director | 2026-04-07 | D | 5,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nanaz Mohtashami | Director | 2026-04-07 | D | 4,536 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-04-07 | D | 7,762 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | D | 7,479 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | D | 6,016 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2026-04-07 | D | 23,775 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2026-04-07 | D | 23,767 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 1,146,829 | — | — | Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2026-04-07 | D | 11,596 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2026-04-07 | D | 42,707 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2026-04-07 | D | 30,774 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2026-04-07 | A | 22,598 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2026-04-07 | D | 17,964 | — | — | Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 5,396 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-04-07 | D | 5,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-04-07 | D | 2,012 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Wayde D. McMillan | Director | 2026-04-07 | D | 5,171 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stacey D. Stewart | Director | 2026-04-07 | D | 768 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stacey D. Stewart | Director | 2026-04-07 | D | 8,358 | — | — | Deferred share award | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 5,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | D | 4,683 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2026-04-07 | A | 42,707 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2026-04-07 | D | 21,743 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2026-04-07 | D | 150,735 | — | — | Deferred share award | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 12,490 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 159,339 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 6,523 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 1,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-04-07 | D | 3,505 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-04-07 | D | 23,026 | — | — | Deferred share award | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | D | 5,943 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2026-04-07 | D | 8,432 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2026-04-07 | A | 5,665 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-04-07 | A | 7,762 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | A | 31,409 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | A | 190,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 19,327 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 17,831 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 12,509 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 15,387 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 7,564 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 134,039 | — | — | Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 6,523 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 7,551 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stacey D. Stewart | Director | 2026-04-07 | D | 4,536 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stacey D. Stewart | Director | 2026-04-07 | D | 4,210 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 4,536 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 4,210 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 5,293 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 5,055 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 7,322 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 7,551 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Amy M. Wendell | Director | 2026-04-07 | D | 25,784 | — | — | Common | Form 4 ↗ |
| De Walt Diana | SVP, Human Resources | 2026-04-07 | D | 7,603 | — | — | Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-04-07 | D | 2,844 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-04-07 | D | 3,509 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-04-07 | D | 2,899 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-04-07 | D | 5,349 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2026-04-07 | A | 46,154 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mark W. Horvath | President, Breast & Skeletal | 2026-04-07 | D | 2,490 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2026-04-07 | D | 3,509 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2026-04-07 | D | 7,505 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | D | 5,121 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | D | 6,129 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | D | 2,173 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Anne M. Liddy | General Counsel | 2026-04-07 | D | 28,052 | — | — | Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2026-04-07 | D | 46,154 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2026-04-07 | D | 32,722 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2026-04-07 | D | 25,070 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2026-04-07 | D | 18,698 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2026-04-07 | D | 2,972 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2026-04-07 | D | 28,047 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karleen Oberton | Chief Financial Officer | 2026-04-07 | D | 25,070 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2026-04-07 | D | 10,028 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2026-04-07 | D | 4,058 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2026-04-07 | D | 3,804 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2026-04-07 | D | 41,462 | — | — | Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2026-04-07 | A | 8,432 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2026-04-07 | D | 8,414 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2026-04-07 | D | 2,538 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2026-04-07 | D | 5,014 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2026-04-07 | D | 3,865 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2026-04-07 | D | 2,265 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandon Schnittker | President, GYN Surgical | 2026-04-07 | D | 17,644 | — | — | Common | Form 4 ↗ |
| Benjamin Jordan Cohn | Principal Accounting Officer | 2026-04-07 | D | 10,861 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 5,293 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 7,322 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 6,523 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 6,626 | — | — | Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-04-07 | D | 4,536 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-04-07 | D | 4,210 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-04-07 | D | 5,293 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-04-07 | D | 6,523 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 190,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 117,829 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 106,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 118,877 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 160,565 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Madaus | Director | 2026-04-07 | D | 5,445 | — | — | Common | Form 4 ↗ |
| Nanaz Mohtashami | Director | 2026-04-07 | D | 7,371 | — | — | Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 4,210 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 31,409 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 20,056 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 4,536 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 6,816 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 50,526 | — | — | Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 5,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 5,293 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 5,055 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Christiana Stamoulis | Director | 2026-04-07 | D | 7,322 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 5,055 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 5,535 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 4,536 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 4,210 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles J. Dockendorff | Director | 2026-04-07 | D | 15,370 | — | — | Common | Form 4 ↗ |
| Essex Mitchell | Chief Operating Officer | 2026-04-07 | D | 77,694 | — | — | Common | Form 4 ↗ |
| Ludwig N. Hantson | Director | 2026-04-07 | D | 7,322 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nanaz Mohtashami | Director | 2026-04-07 | D | 2,141 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 117,801 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 123,801 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 152,529 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 151,071 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 768,639 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Martin Madaus | Director | 2026-04-07 | D | 5,396 | — | — | Common | Form 4 ↗ |
| Jan Verstreken | Group President, International | 2026-04-07 | D | 18,698 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Stephen P. MacMillan | Director | 2026-04-07 | D | 1,423,837 | — | — | Deferred share award | Form 4 ↗ |
| Jennifer M. Schneiders | President, Diag. Solutions | 2026-04-07 | D | 22,598 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jan Verstreken | PSU | 2023-11-14 | 1,737 | 3,475 | — | 6,950 | $306,009 |
| Karleen Oberton | PSU | 2023-11-14 | 2,171 | 4,343 | — | 8,686 | 312,435 |
| Essex Mitchell | PSU | 2023-11-14 | 2,171 | 4,343 | — | 8,686 | 312,435 |
| Essex Mitchell | PSU | 2023-11-14 | 2,171 | 4,343 | — | 8,686 | 382,445 |
| Stephen MacMillan | PSU | 2023-11-14 | 20,416 | 40,832 | — | 81,664 | 2,937,454 |
| Karleen Oberton | PSU | 2023-11-14 | 4,343 | 8,687 | — | 17,374 | 624,943 |
| John Griffin | PSU | 2023-11-14 | 3,475 | 6,950 | — | 13,900 | 499,983 |
| John Griffin | PSU | 2023-11-14 | 1,737 | 3,475 | — | 6,950 | 306,009 |
| Karleen Oberton | RSU | 2023-11-14 | — | — | 8,687 | — | 624,943 |
| Jan Verstreken | PSU | 2023-11-14 | 1,737 | 3,475 | — | 6,950 | 249,992 |
| Essex Mitchell | PSU | 2023-11-14 | 4,343 | 8,687 | — | 17,374 | 624,943 |
| Karleen Oberton | PSU | 2023-11-14 | 2,171 | 4,343 | — | 8,686 | 382,445 |
| Essex Mitchell | RSU | 2023-11-14 | — | — | 8,687 | — | 624,943 |
| Stephen MacMillan | RSU | 2023-11-14 | — | — | 40,832 | — | 2,937,454 |
| John Griffin | PSU | 2023-11-14 | 1,737 | 3,475 | — | 6,950 | 249,992 |
| Essex Mitchell | OPTION | 2023-11-14 | — | — | 25,070 | — | 624,995 |
| Jan Verstreken | RSU | 2023-11-14 | — | — | 6,950 | — | 499,983 |
| Stephen MacMillan | PSU | 2023-11-14 | 10,208 | 20,416 | — | 40,832 | 1,468,727 |
| John Griffin | RSU | 2023-11-14 | — | — | 6,950 | — | 499,983 |
| Stephen MacMillan | PSU | 2023-11-14 | 10,208 | 20,416 | — | 40,832 | 1,797,833 |
| Jan Verstreken | PSU | 2023-11-14 | 3,475 | 6,950 | — | 13,900 | 499,983 |
| John Griffin | OPTION | 2023-11-14 | — | — | 20,056 | — | 499,996 |
| Stephen MacMillan | OPTION | 2023-11-14 | — | — | 117,829 | — | 2,937,477 |
| Jan Verstreken | OPTION | 2023-11-14 | — | — | 20,056 | — | 499,996 |
| Karleen Oberton | OPTION | 2023-11-14 | — | — | 25,070 | — | 624,995 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jan Verstreken | $499,983 | $1,055,984 | $499,996 | 51.4% |
| Karleen Oberton | 624,943 | 1,319,823 | 624,995 | 51.4% |
| Essex Mitchell | 624,943 | 1,319,823 | 624,995 | 51.4% |
| Stephen MacMillan | 2,937,454 | 6,204,014 | 2,937,477 | 51.4% |
| John Griffin | 499,983 | 1,055,984 | 499,996 | 51.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Karleen Oberton | PSU | 17,374 | — | $1,404,167 |
| Essex Mitchell | RSU | 2,690 | — | 217,406 |
| Jan Verstreken | RSU | 1,758 | — | 142,082 |
| Stephen MacMillan | RSU | 34,209 | — | 2,764,792 |
| Jan Verstreken | RSU | 5,130 | — | 414,642 |
| Essex Mitchell | Option | 8,697 | 74.35 | — |
| John Griffin | PSU | 13,900 | — | 1,123,398 |
| Stephen MacMillan | PSU | 73,974 | — | 5,978,579 |
| John Griffin | RSU | 2,050 | — | 165,681 |
| Stephen MacMillan | PSU | 40,832 | — | 3,300,042 |
| Stephen MacMillan | RSU | 40,832 | — | 3,300,042 |
| John Griffin | PSU | 12,104 | — | 978,245 |
| Stephen MacMillan | PSU | 81,664 | — | 6,600,084 |
| Stephen MacMillan | RSU | 46,862 | — | 3,787,387 |
| Essex Mitchell | PSU | 8,068 | — | 652,056 |
| Stephen MacMillan | RSU | 37,490 | — | 3,029,909 |
| Stephen MacMillan | PSU | 36,986 | — | 2,989,209 |
| Stephen MacMillan | RSU | 24,658 | — | 1,992,860 |
| Essex Mitchell | PSU | 17,374 | — | 1,404,167 |
| Karleen Oberton | PSU | 15,130 | — | 1,222,807 |
| Jan Verstreken | PSU | 13,900 | — | 1,123,398 |
| Jan Verstreken | PSU | 13,448 | — | 1,086,867 |
| Stephen MacMillan | RSU | 11,716 | — | 946,887 |
| Karleen Oberton | RSU | 9,372 | — | 757,445 |
| Karleen Oberton | RSU | 8,687 | — | 702,083 |
| Essex Mitchell | RSU | 8,687 | — | 702,083 |
| Karleen Oberton | PSU | 8,686 | — | 702,003 |
| Karleen Oberton | Option | 5,942 | 68.35 | — |
| Essex Mitchell | PSU | 8,686 | — | 702,003 |
| John Griffin | RSU | 8,200 | — | 662,724 |
| Karleen Oberton | PSU | 7,564 | — | 611,322 |
| Karleen Oberton | RSU | 7,498 | — | 605,956 |
| Jan Verstreken | RSU | 7,028 | — | 568,003 |
| John Griffin | RSU | 6,950 | — | 561,699 |
| John Griffin | PSU | 6,950 | — | 561,699 |
| Jan Verstreken | RSU | 6,950 | — | 561,699 |
| Jan Verstreken | PSU | 6,950 | — | 561,699 |
| John Griffin | Option | 5,317 | 68.35 | — |
| Karleen Oberton | RSU | 6,842 | — | 552,935 |
| Jan Verstreken | PSU | 6,724 | — | 543,434 |
| Jan Verstreken | Option | 20,056 | 71.94 | — |
| John Griffin | RSU | 6,560 | — | 530,179 |
| John Griffin | PSU | 6,052 | — | 489,123 |
| John Griffin | RSU | 5,986 | — | 483,789 |
| Karleen Oberton | RSU | 2,343 | — | 189,361 |
| Jan Verstreken | RSU | 5,622 | — | 454,402 |
| Karleen Oberton | RSU | 5,044 | — | 407,656 |
| Essex Mitchell | RSU | 4,686 | — | 378,723 |
| Jan Verstreken | RSU | 4,483 | — | 362,316 |
| John Griffin | RSU | 4,035 | — | 326,109 |
| Essex Mitchell | PSU | 4,034 | — | 326,028 |
| Essex Mitchell | RSU | 3,749 | — | 302,978 |
| Karleen Oberton | Option | 16,308 | 74.35 | — |
| Essex Mitchell | RSU | 3,421 | — | 276,467 |
| Essex Mitchell | RSU | 1,172 | — | 94,721 |
| Stephen MacMillan | Option | 30,951 | 68.35 | — |
| Stephen MacMillan | Option | 59,439 | 71.13 | — |
| Stephen MacMillan | Option | 79,725 | 74.35 | — |
| Stephen MacMillan | Option | 117,829 | 71.94 | — |
| Karleen Oberton | Option | 11,888 | 71.13 | — |
| Karleen Oberton | Option | 25,070 | 71.94 | — |
| Essex Mitchell | Option | 1,877 | 68.35 | — |
| Jan Verstreken | Option | 3,128 | 68.35 | — |
| Essex Mitchell | Option | 5,944 | 71.13 | — |
| Essex Mitchell | Option | 25,070 | 71.94 | — |
| John Griffin | Option | 10,402 | 71.13 | — |
| John Griffin | Option | 13,046 | 74.35 | — |
| John Griffin | Option | 20,056 | 71.94 | — |
| Jan Verstreken | Option | 8,916 | 71.13 | — |
| Jan Verstreken | Option | 14,496 | 74.35 | — |
Hologic's compensation program is guided by principles of pay for performance, competitive pay, and a focus on total direct compensation. The design aims to motivate high performance within an entrepreneurial culture, ensure target compensation is competitive with peers, and support leadership talent through a mix of fixed and variable pay.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-02-26 | 169,811,160 | 33,412,544 | 224,944 | 83.56% | Passed |
| 2024 | 2024-03-07 | 157,469,578 | 42,018,967 | 210,448 | 78.94% | Passed |
| 2023 | 2023-03-09 | 167,512,931 | 49,838,936 | 429,644 | 77.07% | Passed |
| 2022 | 2022-03-10 | 150,939,075 | 63,245,865 | 846,610 | 70.47% | Passed |
| 2021 | 2021-03-11 | 154,538,680 | 69,327,387 | 546,595 | 69.03% | Passed |
| 2020 | 2020-03-05 | 185,555,444 | 39,060,828 | 1,687,899 | 82.61% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-02-26 | 83.56%a |
| 2024 | 2024-03-07 | 78.94%b |
| 2023 | 2023-03-09 | 77.07%c |
a. Approved under the standard stated in the filing — “Abstentions and broker "non-votes" are included in the number of shares present or represented for purposes of quorum but are disregarded for purposes of determining whether any of the proposals have been approved.”.
b. Approved under the standard stated in the filing — “Abstentions and broker "non-votes" are included in the number of shares present or represented for purposes of quorum but are disregarded for purposes of determining whether any of the proposals have been approved.”.
c. Approved under the standard stated in the filing — “Abstentions and broker "non-votes" are included in the number of shares present or represented for purposes of quorum but are disregarded for purposes of determining whether any of the proposals have been approved.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 137 : 1 |
|---|---|
| CEO total compensation | $12,040,142 |
| Median employee compensation | $87,845 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Amy M. WendellIndependent · Lead Independent Director · Compensation · Nominating and Corporate Governance (Chair) | $117,500 | $119,975 | $119,977 | — | — | $357,452 |
| Sally W. CrawfordIndependent · Compensation · Nominating and Corporate Governance · Not standing for re-election | 117,500 | 119,975 | 119,977 | — | — | 357,452 |
| Charles J. DockendorffIndependent · Audit and Finance (Chair) | 115,000 | 119,975 | 119,977 | — | — | 354,952 |
| Scott T. GarrettIndependent · Compensation (Chair) · Nominating and Corporate Governance · Not standing for re-election | 110,000 | 119,975 | 119,977 | — | — | 349,952 |
| Stacey D. StewartIndependent · Audit and Finance | 90,000 | 119,975 | 119,977 | — | — | 329,952 |
| Nanaz MohtashamiIndependent · Compensation · Nominating and Corporate Governance | 90,000 | 119,975 | 119,977 | — | — | 329,952 |
| Christiana StamoulisIndependent · Audit and Finance | 90,000 | 119,975 | 119,977 | — | — | 329,952 |
| Ludwig N. HantsonIndependent · Compensation · Nominating and Corporate Governance | 90,000 | 119,975 | 119,977 | — | — | 329,952 |
| Namal NawanaIndependent · Not standing for re-election | 45,000 | 0 | 0 | — | — | 45,000 |
| Stephen P. MacMillanEmployee director · Board Chair | — | — | — | — | — | 0 |
| Martin MadausIndependent · Compensation · Nominating and Corporate Governance · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $90,000 |
|---|---|
| Annual equity retainer | $240,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | 5x annual base cash retainer |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $865,000 |
| Equity awards (grant-date value) | $959,800 |
| All other compensation | $0 |
| Total cost of the board | $1,824,800 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies HOLOGIC INC names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including HOLOGIC INC.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc. | 2025 | Marc Casper | $1,785,534 | $65,730,211 | $7,951,377 | $3,742,123 | $79,923,350 |
| 2 | Johnson & Johnson | 2025 | Joaquin Duato | 1,600,000 | 15,028,948 | 5,927,995 | 4,298,700 | 32,758,111 |
| 3 | Baxter International Inc. | 2025 | Andrew Hider | 499,315 | 23,133,518 | 3,185,053 | 820,125 | 29,805,182 |
| 4 | Abbott Laboratories | 2025 | Robert Ford | 1,500,000 | 8,787,378 | 8,788,430 | 1,968,750 | 24,198,660 |
| 5 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 6 | Stryker Corporation | 2025 | Kevin Lobo | 1,500,000 | 9,764,136 | 6,920,781 | 2,250,000 | 21,401,495 |
| 7 | Intuitive Surgical, Inc. | 2025 | David Rosa | 858,750 | 18,674,872 | 0 | 1,373,859 | 20,997,480 |
| 8 | Edwards Lifesciences Corp. | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 9 | Becton, Dickinson and Company | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 10 | ResMed Inc. | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 11 | Zimmer Biomet Holdings, Inc. | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 12 | The Cooper Companies, Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 13 | HOLOGIC INC | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 14 | Quest Diagnostics Inc. | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 15 | IDEXX Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 16 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 17 | Revvity, Inc. | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 18 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 19 | STERIS plc | 2026 | Daniel Carestio | 1,095,707 | 4,333,951 | 4,334,251 | 1,725,007 | 11,508,522 |
| 20 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 21 | Integra LifeSciences Holdings Corp | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 22 | DENTSPLY SIRONA Inc. | 2025 | Daniel Scavilla | 431,753 | 3,484,488 | 3,221,523 | 437,150 | 8,760,139 |
| 23 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 24 | Mettler-Toledo International Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
| 25 | Teleflex Incorporated | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 26 | Bruker Corporation | 2025 | Frank Laukien | 976,554 | 1,623,407 | 1,488,109 | 587,270 | 4,706,388 |
| — | Qiagen NV | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| HOLOGIC INC | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Abbott Laboratories | 75.0% | Options 50 · PSU 50 | No | Meridian Compensation Partners, LLC |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Baxter International Inc. | not disclosed | not disclosed | No | Aon Consulting, Inc. (Aon) |
| Becton, Dickinson and Company | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| Bruker Corporation | 43.0% | RSU 52 · Options 48 | not disclosed | Aon's Human Capital Solutions Practice |
| DENTSPLY SIRONA Inc. | 66% | PSU 50 · Options 50 | No | Frederic W. Cook & Co., Inc. |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Edwards Lifesciences Corp. | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| IDEXX Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Integra LifeSciences Holdings Corp | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| Intuitive Surgical, Inc. | 115.2% | RSU 50 · PSU 50 | No | Aon |
| Johnson & Johnson | not disclosed | not disclosed | Yes — Relative TSR | Semler Brossy Consulting Group |
| Mettler-Toledo International Inc. | not disclosed | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners |
| Qiagen NV | not disclosed | not disclosed | not disclosed | not disclosed |
| Quest Diagnostics Inc. | 113.9% | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | Semler Brossy |
| ResMed Inc. | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Revvity, Inc. | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| STERIS plc | 125.1% | RSU 50 · Options 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Stryker Corporation | 100% | PSU 48 · Options 34 | No | Semler Brossy |
| Teleflex Incorporated | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
| The Cooper Companies, Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Thermo Fisher Scientific Inc. | 99.8% | PSU 50 · Options 50 | Yes — Relative TSR | Pearl Meyer |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| Zimmer Biomet Holdings, Inc. | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Stephen MacMillan | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Summary Compensation Table”. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 2 | Section 01, Karleen Oberton | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Summary Compensation Table”. As printed: 4,090,438. Filing ↗machine: r5 · c25 · span 1564568–1564577 |
| 3 | Section 01, Essex Mitchell | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Summary Compensation Table”. As printed: 4,083,725. Filing ↗machine: r8 · c25 · span 1580010–1580019 |
| 4 | Section 01, Jan Verstreken | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Summary Compensation Table”. As printed: 3,585,895. Filing ↗machine: r13 · c25 · span 1605785–1605794 |
| 5 | Section 01, John Griffin | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Summary Compensation Table”. As printed: 3,474,051. Filing ↗machine: r10 · c25 · span 1590421–1590430 |
| 6 | Section 03, Jan Verstreken PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r30 · c19 · span 1847820–1847825 |
| 7 | Section 03, Karleen Oberton PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r12 · c19 · span 1722083–1722088 |
| 8 | Section 03, Essex Mitchell PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r18 · c19 · span 1763979–1763984 |
| 9 | Section 03, Essex Mitchell PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r18 · c19 · span 1763979–1763984 |
| 10 | Section 03, Stephen MacMillan PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r4 · c28 · span 1668498–1668504 |
| 11 | Section 03, Karleen Oberton PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r10 · c28 · span 1709819–1709824 |
| 12 | Section 03, John Griffin PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r22 · c28 · span 1793649–1793654 |
| 13 | Section 03, John Griffin PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r24 · c19 · span 1805913–1805918 |
| 14 | Section 03, Karleen Oberton RSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r10 · c28 · span 1709819–1709824 |
| 15 | Section 03, Jan Verstreken PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r30 · c19 · span 1847820–1847825 |
| 16 | Section 03, Essex Mitchell PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r16 · c28 · span 1751715–1751720 |
| 17 | Section 03, Karleen Oberton PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r12 · c19 · span 1722083–1722088 |
| 18 | Section 03, Essex Mitchell RSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r16 · c28 · span 1751715–1751720 |
| 19 | Section 03, Stephen MacMillan RSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r4 · c28 · span 1668498–1668504 |
| 20 | Section 03, John Griffin PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r24 · c19 · span 1805913–1805918 |
| 21 | Section 03, Essex Mitchell OPTION | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r17 · c31 · span 1759101–1759107 |
| 22 | Section 03, Jan Verstreken RSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r28 · c28 · span 1835556–1835561 |
| 23 | Section 03, Stephen MacMillan PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r6 · c19 · span 1680599–1680605 |
| 24 | Section 03, John Griffin RSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r22 · c28 · span 1793649–1793654 |
| 25 | Section 03, Stephen MacMillan PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r6 · c19 · span 1680599–1680605 |
| 26 | Section 03, Jan Verstreken PSU | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r28 · c28 · span 1835556–1835561 |
| 27 | Section 03, John Griffin OPTION | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r23 · c31 · span 1801035–1801041 |
| 28 | Section 03, Stephen MacMillan OPTION | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r5 · c31 · span 1675802–1675809 |
| 29 | Section 03, Jan Verstreken OPTION | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r29 · c31 · span 1842942–1842948 |
| 30 | Section 03, Karleen Oberton OPTION | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t249 · r11 · c31 · span 1717205–1717211 |
| 31 | Section 07, pay ratio | DEF 14A | 2019-01-18 | 0001206774-19-000140 | Section “CEO Pay Ratio”. As printed: 137 : 1. Filing ↗ |
| 32 | Section 08, Amy M. Wendell | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 357,452. Filing ↗machine: span 838853–839027 |
| 33 | Section 08, Sally W. Crawford | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 357,452. Filing ↗machine: span 816299–816473 |
| 34 | Section 08, Charles J. Dockendorff | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 354,952. Filing ↗machine: span 819151–819326 |
| 35 | Section 08, Scott T. Garrett | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 349,952. Filing ↗machine: span 822013–822188 |
| 36 | Section 08, Stacey D. Stewart | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 329,952. Filing ↗machine: span 836604–836779 |
| 37 | Section 08, Nanaz Mohtashami | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 329,952. Filing ↗machine: span 827792–827967 |
| 38 | Section 08, Christiana Stamoulis | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 329,952. Filing ↗machine: span 833714–833889 |
| 39 | Section 08, Ludwig N. Hantson | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 329,952. Filing ↗machine: span 824903–825078 |
| 40 | Section 08, Namal Nawana | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 45,000. Filing ↗machine: span 828942–829161 |
| 41 | Section 08, Stephen P. MacMillan | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 42 | Section 08, Martin Madaus | DEF 14A | 2025-01-16 | 0001140361-25-001287 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 43 | Section 02, Stephen P. MacMillan 2025-09-22 | Form 4 | 2025-09-23 | 0000859737-25-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Stephen P. MacMillan 2025-09-22 | Form 4 | 2025-09-23 | 0000859737-25-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Stephen P. MacMillan 2025-09-22 | Form 4 | 2025-09-23 | 0000859737-25-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Christiana Stamoulis 2025-10-20 | Form 4 | 2025-10-22 | 0000859737-25-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Christiana Stamoulis 2025-10-20 | Form 4 | 2025-10-22 | 0000859737-25-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Christiana Stamoulis 2025-10-20 | Form 4 | 2025-10-22 | 0000859737-25-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Benjamin Jordan Cohn 2025-11-04 | Form 4 | 2025-11-06 | 0000859737-25-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Karleen Oberton 2025-11-04 | Form 4 | 2025-11-06 | 0000859737-25-000042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Jan Verstreken 2025-11-04 | Form 4 | 2025-11-06 | 0000859737-25-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Stephen P. MacMillan 2025-11-04 | Form 4 | 2025-11-06 | 0000859737-25-000046 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Essex Mitchell 2025-11-04 | Form 4 | 2025-11-06 | 0000859737-25-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Mark W. Horvath 2025-11-04 | Form 4 | 2025-11-06 | 0000859737-25-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Anne M. Liddy 2025-11-07 | Form 4 | 2025-11-12 | 0000859737-25-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Essex Mitchell 2025-11-07 | Form 4 | 2025-11-12 | 0000859737-25-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Karleen Oberton 2025-11-07 | Form 4 | 2025-11-12 | 0000859737-25-000054 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Jennifer M. Schneiders 2025-11-07 | Form 4 | 2025-11-12 | 0000859737-25-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Brandon Schnittker 2025-11-07 | Form 4 | 2025-11-12 | 0000859737-25-000058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Benjamin Jordan Cohn 2025-11-07 | Form 4 | 2025-11-12 | 0000859737-25-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Stephen P. MacMillan 2025-11-07 | Form 4 | 2025-11-12 | 0000859737-25-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Jan Verstreken 2025-11-07 | Form 4 | 2025-11-12 | 0000859737-25-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Anne M. Liddy 2025-11-10 | Form 4 | 2025-11-12 | 0000859737-25-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Mark W. Horvath 2025-11-10 | Form 4 | 2025-11-12 | 0000859737-25-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Karleen Oberton 2025-11-10 | Form 4 | 2025-11-12 | 0000859737-25-000054 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Jennifer M. Schneiders 2025-11-10 | Form 4 | 2025-11-12 | 0000859737-25-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Stephen P. MacMillan 2025-11-10 | Form 4 | 2025-11-12 | 0000859737-25-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Benjamin Jordan Cohn 2025-11-10 | Form 4 | 2025-11-12 | 0000859737-25-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Brandon Schnittker 2025-11-10 | Form 4 | 2025-11-12 | 0000859737-25-000058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Jan Verstreken 2025-11-10 | Form 4 | 2025-11-12 | 0000859737-25-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Essex Mitchell 2025-11-10 | Form 4 | 2025-11-12 | 0000859737-25-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Brandon Schnittker 2025-11-11 | Form 4 | 2025-11-12 | 0000859737-25-000058 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Anne M. Liddy 2025-11-11 | Form 4 | 2025-11-12 | 0000859737-25-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Essex Mitchell 2025-11-11 | Form 4 | 2025-11-12 | 0000859737-25-000052 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Karleen Oberton 2025-11-11 | Form 4 | 2025-11-12 | 0000859737-25-000054 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Jennifer M. Schneiders 2025-11-11 | Form 4 | 2025-11-12 | 0000859737-25-000056 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Jan Verstreken 2025-11-11 | Form 4 | 2025-11-12 | 0000859737-25-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Benjamin Jordan Cohn 2025-11-11 | Form 4 | 2025-11-12 | 0000859737-25-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Stephen P. MacMillan 2025-11-11 | Form 4 | 2025-11-12 | 0000859737-25-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Essex Mitchell 2025-11-14 | Form 4 | 2025-11-18 | 0000859737-25-000078 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Brandon Schnittker 2025-11-14 | Form 4 | 2025-11-18 | 0000859737-25-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Anne M. Liddy 2025-11-14 | Form 4 | 2025-11-18 | 0000859737-25-000076 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Benjamin Jordan Cohn 2025-11-14 | Form 4 | 2025-11-18 | 0000859737-25-000074 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Karleen Oberton 2025-11-14 | Form 4 | 2025-11-18 | 0000859737-25-000080 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Jennifer M. Schneiders 2025-11-14 | Form 4 | 2025-11-18 | 0000859737-25-000082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Stephen P. MacMillan 2025-11-14 | Form 4 | 2025-11-18 | 0000859737-25-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Jan Verstreken 2025-11-14 | Form 4 | 2025-11-18 | 0000859737-25-000086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Brandon Schnittker 2025-12-12 | Form 4 | 2025-12-16 | 0000859737-25-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, De Walt Diana 2026-01-30 | Form 4 | 2026-02-03 | 0000859737-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, De Walt Diana 2026-01-30 | Form 4 | 2026-02-03 | 0000859737-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Mark W. Horvath 2026-02-10 | Form 4 | 2026-02-12 | 0000859737-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Nanaz Mohtashami 2026-02-26 | Form 4 | 2026-03-02 | 0000859737-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Stacey D. Stewart 2026-02-26 | Form 4 | 2026-03-02 | 0000859737-26-000029 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Martin Madaus 2026-02-26 | Form 4 | 2026-03-02 | 0000859737-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Wayde D. McMillan 2026-02-26 | Form 4 | 2026-03-02 | 0000859737-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Amy M. Wendell 2026-02-26 | Form 4 | 2026-03-02 | 0000859737-26-000031 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Christiana Stamoulis 2026-02-26 | Form 4 | 2026-03-02 | 0000859737-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Ludwig N. Hantson 2026-02-26 | Form 4 | 2026-03-02 | 0000859737-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Charles J. Dockendorff 2026-02-26 | Form 4 | 2026-03-02 | 0000859737-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Anne M. Liddy 2026-02-27 | Form 4 | 2026-03-02 | 0000859737-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Ludwig N. Hantson 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Wayde D. McMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Benjamin Jordan Cohn 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Martin Madaus 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Stacey D. Stewart 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Benjamin Jordan Cohn 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Benjamin Jordan Cohn 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Benjamin Jordan Cohn 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Ludwig N. Hantson 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Martin Madaus 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Nanaz Mohtashami 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Nanaz Mohtashami 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Mark W. Horvath 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Karleen Oberton 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Karleen Oberton 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Essex Mitchell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Karleen Oberton 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Karleen Oberton 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Jennifer M. Schneiders 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Benjamin Jordan Cohn 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Ludwig N. Hantson 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Ludwig N. Hantson 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Wayde D. McMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Stacey D. Stewart 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Stacey D. Stewart 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Karleen Oberton 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Karleen Oberton 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Karleen Oberton 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Mark W. Horvath 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Mark W. Horvath 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Brandon Schnittker 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Benjamin Jordan Cohn 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Mark W. Horvath 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Stacey D. Stewart 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Stacey D. Stewart 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Amy M. Wendell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, De Walt Diana 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000079 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Mark W. Horvath 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Mark W. Horvath 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Mark W. Horvath 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Mark W. Horvath 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Essex Mitchell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Mark W. Horvath 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000081 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Benjamin Jordan Cohn 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Benjamin Jordan Cohn 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Anne M. Liddy 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000083 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Essex Mitchell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Essex Mitchell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Essex Mitchell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, Jennifer M. Schneiders 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Essex Mitchell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, Karleen Oberton 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Karleen Oberton 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, Jennifer M. Schneiders 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Jennifer M. Schneiders 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Jennifer M. Schneiders 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Jennifer M. Schneiders 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Brandon Schnittker 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Brandon Schnittker 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Brandon Schnittker 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, Brandon Schnittker 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Brandon Schnittker 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Brandon Schnittker 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, Brandon Schnittker 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000091 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, Benjamin Jordan Cohn 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000059 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, Ludwig N. Hantson 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, Ludwig N. Hantson 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, Ludwig N. Hantson 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, Ludwig N. Hantson 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 212 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 213 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 214 | Section 02, Martin Madaus 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 215 | Section 02, Nanaz Mohtashami 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 216 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 217 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 218 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 219 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 220 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 221 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 222 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 223 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 224 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 225 | Section 02, Christiana Stamoulis 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 226 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 227 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 228 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 229 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 230 | Section 02, Charles J. Dockendorff 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000061 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 231 | Section 02, Essex Mitchell 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 232 | Section 02, Ludwig N. Hantson 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 233 | Section 02, Nanaz Mohtashami 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 234 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 235 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 236 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 237 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 238 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 239 | Section 02, Martin Madaus 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 240 | Section 02, Jan Verstreken 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000093 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 241 | Section 02, Stephen P. MacMillan 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 242 | Section 02, Jennifer M. Schneiders 2026-04-07 | Form 4 | 2026-04-09 | 0000859737-26-000089 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 243 | Section 06, 2025 vote | Form 8-K | 2025-02-28 | 0001140361-25-006521 | Item 5.07 · say-on-pay result. As reported: 83.56% (votes for as printed: 169,811,160). Filing ↗ |
| 244 | Section 06, 2024 vote | Form 8-K | 2024-03-12 | 0000859737-24-000009 | Item 5.07 · say-on-pay result. As reported: 78.94% (votes for as printed: 157,469,578). Filing ↗ |
| 245 | Section 06, 2023 vote | Form 8-K | 2023-03-10 | 0000859737-23-000006 | Item 5.07 · say-on-pay result. As reported: 77.07% (votes for as printed: 167,512,931). Filing ↗ |
| 246 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 247 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 248 | Section 09b board cost (computed) | Computed | — | — | Cash 865,000 + equity 959,800 + all other 0 = 1,824,800, summed across the director compensation table rows.machine: formula: Σ = 1,824,800 |
| 249 | Thermo Fisher Scientific Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-144585 | CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. Filing ↗machine: span 973487–973497 |
| 250 | Johnson & Johnson, Section 10b CEO total | DEF 14A | 2026-03-11 | 0000200406-26-000063 | CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246 |
| 251 | Baxter International Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001628280-26-020330 | CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076 |
| 252 | Abbott Laboratories, Section 10b CEO total | DEF 14A | 2026-03-13 | 0001308179-26-000064 | CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. Filing ↗machine: span 1245488–1245498 |
| 253 | Boston Scientific Corporation, Section 10b CEO total | DEF 14A | 2026-03-18 | 0000885725-26-000025 | CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817 |
| 254 | Stryker Corporation, Section 10b CEO total | DEF 14A | 2026-03-23 | 0000310764-26-000013 | CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. Filing ↗machine: t101 · r2 · c7 · span 1584979–1584989 |
| 255 | Intuitive Surgical, Inc., Section 10b CEO total | DEF 14A | 2026-03-13 | 0001035267-26-000023 | CEO total compensation as printed in Intuitive Surgical, Inc.'s own proxy. As printed: 20,997,480. Filing ↗machine: r2 · c48 · span 762289–762299 |
| 256 | Edwards Lifesciences Corp., Section 10b CEO total | DEF 14A | 2026-03-26 | 0001099800-26-000015 | CEO total compensation as printed in Edwards Lifesciences Corp.'s own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451 |
| 257 | Becton, Dickinson and Company, Section 10b CEO total | DEF 14A | 2025-12-18 | 0001628280-25-057846 | CEO total compensation as printed in Becton, Dickinson and Company's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 258 | ResMed Inc., Section 10b CEO total | DEF 14A | 2026-10-01 | 0000943819-26-000080 | CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. Filing ↗machine: span 1267106–1267116 |
| 259 | Zimmer Biomet Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001193125-26-135661 | CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. Filing ↗machine: t111 · r3 · c16 · span 1895785–1895795 |
| 260 | The Cooper Companies, Inc., Section 10b CEO total | DEF 14A | 2026-02-24 | 0001628280-26-011110 | CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914 |
| 261 | HOLOGIC INC (subject), Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in HOLOGIC INC's own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 262 | Quest Diagnostics Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013356 | CEO total compensation as printed in Quest Diagnostics Inc.'s own proxy. As printed: 15,498,479. Filing ↗machine: r2 · c17 · span 699327–699337 |
| 263 | IDEXX Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 264 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 265 | Revvity, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-107266 | CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: r3 · c39 · span 751285–751295 |
| 266 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 267 | STERIS plc, Section 10b CEO total | DEF 14A | 2026-06-11 | 0001193125-26-267599 | CEO total compensation as printed in STERIS plc's own proxy. As printed: 11,508,522. Filing ↗machine: t172 · r6 · c34 · span 820590–820600 |
| 268 | Illumina, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 269 | Integra LifeSciences Holdings Corp, Section 10b CEO total | DEF 14A | 2026-04-06 | 0000917520-26-000015 | CEO total compensation as printed in Integra LifeSciences Holdings Corp's own proxy. As printed: 9,375,551. Filing ↗machine: r2 · c30 · span 880204–880213 |
| 270 | DENTSPLY SIRONA Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0000818479-26-000125 | CEO total compensation as printed in DENTSPLY SIRONA Inc.'s own proxy. As printed: 8,760,139. Filing ↗machine: r5 · c27 · span 1201378–1201387 |
| 271 | DexCom, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001093557-26-000061 | CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373 |
| 272 | Mettler-Toledo International Inc., Section 10b CEO total | DEF 14A | 2026-03-18 | 0001174947-26-000389 | CEO total compensation as printed in Mettler-Toledo International Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538 |
| 273 | Teleflex Incorporated, Section 10b CEO total | DEF 14A | 2026-04-13 | 0000096943-26-000039 | CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. Filing ↗machine: span 558736–558745 |
| 274 | Bruker Corporation, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151305 | CEO total compensation as printed in Bruker Corporation's own proxy. As printed: 4,706,388. Filing ↗machine: t77 · r2 · c18 · span 987303–987312 |
| 275 | Section 10a, Revvity, Inc. reciprocity | DEF 14A | — | 0001193125-26-107266 | Revvity, Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 276 | Section 10a, Becton, Dickinson and Company reciprocity | DEF 14A | — | 0001628280-25-057846 | Becton, Dickinson and Company's most recent proxy was read; its disclosed peer group does not include HOLOGIC INC. Filing ↗ |
| 277 | Section 10a, Stryker Corporation reciprocity | DEF 14A | — | 0000310764-26-000013 | Stryker Corporation's most recent proxy was read; its disclosed peer group does not include HOLOGIC INC. Filing ↗ |
| 278 | Section 10a, Integra LifeSciences Holdings Corp reciprocity | DEF 14A | — | 0000917520-26-000015 | Integra LifeSciences Holdings Corp names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 279 | Section 10a, Quest Diagnostics Inc. reciprocity | DEF 14A | — | 0001140361-26-013356 | Quest Diagnostics Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 280 | Section 10a, Baxter International Inc. reciprocity | DEF 14A | — | 0001628280-26-020330 | Baxter International Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 281 | Section 10a, Intuitive Surgical, Inc. reciprocity | DEF 14A | — | 0001035267-26-000023 | Intuitive Surgical, Inc.'s most recent proxy was read; its disclosed peer group does not include HOLOGIC INC. Filing ↗ |
| 282 | Section 10a, Bruker Corporation reciprocity | DEF 14A | — | 0001193125-26-151305 | Bruker Corporation names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 283 | Section 10a, The Cooper Companies, Inc. reciprocity | DEF 14A | — | 0001628280-26-011110 | The Cooper Companies, Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 284 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 285 | Section 10a, Boston Scientific Corporation reciprocity | DEF 14A | — | 0000885725-26-000025 | Boston Scientific Corporation names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 286 | Section 10a, Zimmer Biomet Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-135661 | Zimmer Biomet Holdings, Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 287 | Section 10a, IDEXX Laboratories, Inc. reciprocity | DEF 14A | — | 0000874716-26-000064 | IDEXX Laboratories, Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 288 | Section 10a, ResMed Inc. reciprocity | DEF 14A | — | 0000943819-26-000080 | ResMed Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 289 | Section 10a, STERIS plc reciprocity | DEF 14A | — | 0001193125-26-267599 | STERIS plc names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 290 | Section 10a, Mettler-Toledo International Inc. reciprocity | DEF 14A | — | 0001174947-26-000389 | Mettler-Toledo International Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 291 | Section 10a, DENTSPLY SIRONA Inc. reciprocity | DEF 14A | — | 0000818479-26-000125 | DENTSPLY SIRONA Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 292 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 293 | Section 10a, DexCom, Inc. reciprocity | DEF 14A | — | 0001093557-26-000061 | DexCom, Inc. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 294 | Section 10a, Edwards Lifesciences Corp. reciprocity | DEF 14A | — | 0001099800-26-000015 | Edwards Lifesciences Corp. names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 295 | Section 10a, Teleflex Incorporated reciprocity | DEF 14A | — | 0000096943-26-000039 | Teleflex Incorporated names HOLOGIC INC in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 296 | Section 10a, Johnson & Johnson reciprocity | DEF 14A | — | 0000200406-26-000063 | Johnson & Johnson's most recent proxy was read; its disclosed peer group does not include HOLOGIC INC. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the HOLOGIC INC Executive Compensation Report
$1,500